Regarding the immunological mechanisms underlying the observed enhancement of the tumor-specific immune response, we evaluated the effects of tumor antigen-loaded DCs plus lenalidomide combination therapy on inhibitory cytokine IL-10 production. This evidence concerns the gene IL10 and neoplasm.